Senores Pharmaceuticals Ltd. · NSE:SENORES
Senores Pharmaceuticals — H1 FY27 Earnings Presentation
34 slides from Senores Pharmaceuticals's earnings presentation, October 2026
Slide 1: Investor Presentation
Investor Presentation October 2026
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for a
Slide 3: Financial & Operational Highlights Q2 & H1FY27
Financial & Operational Highlights Q2 & H1FY27 Private & Confidential
Slide 4: Key Highlights – Q2 & H1FY27
Key Highlights – Q2 & H1FY27 Consistently strong delivery REVENUE GROWTH EBITDA GROWTH EBITDA MARGIN EXPANSION CASH FROM OPERATIONS 25% 30% 38.4% 58.2% ~290 bps ~530 bps ₹38 Cr ₹31 Cr Q2 FY27 H1 FY27 Q2 FY27 H1 FY27 Q2 FY27 H1 FY27 H1 FY27 H1 FY26 Strong EBITDA growth even while investing for the fu
Slide 5: Regulated Market Owned Product Portfolio & Visibility
Regulated Market Owned Product Portfolio & Visibility Owned ANDAs Corresponding ANDA Products* Key Highlights Q2FY26 Q2FY27 Q2FY26 Q2FY27 Approved ANDAs 34 64 81 207 • Commercialized 3 new strengths in Q2FY27 under existing ANDAs, including 2 being sold in the US for the first time by any company. •
Slide 6: CDMO / CMO & Emerging Market Opportunity
CDMO / CMO & Emerging Market Opportunity Regulated Markets ANDAs Corresponding ANDA Products* Huge Opportunity Q2FY26 Q2FY27 Q2FY26 Q2FY27 CDMO/CMO business focused on specialty, government supplies CDMO/ CMO and controlled substances. Commercialized Products 16 19 32 46 Uniquely positioned in USA &
Slide 7: Consolidated Financial Highlights – Q2 & H1FY27
Consolidated Financial Highlights – Q2 & H1FY27 Revenue (₹ Crs) EBITDA (₹ Crs) PAT (₹ Crs) +30% +58% +31% 372.5 111.4 67.0 286.5 22% 51.3 25% 38% 70.4 192.3 57.7 36.6 153.9 30.1 41.7 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1FY27 Gross Margin (%) EBITD
Slide 8: Segmental Financial Highlights – Q2 & H1FY27
Segmental Financial Highlights – Q2 & H1FY27 Segment Revenue (₹ Crs) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Regulated Markets 136.7 106.9 27.9% 264.5 196.9 34.3% Emerging Markets 38.4 31.7 21.2% 76.0 60.7 25.3% Branded Generics 9.5 11.9 -20.5% 17.5 20.2 -13.4% Others 7.8 3.4 126.2% 14.6 8.7 67.2% T
Slide 9: Consolidated Profit & Loss Account – Q2 & H1FY27
Consolidated Profit & Loss Account – Q2 & H1FY27 Consolidated P&L (₹ Crs) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 192.3 153.9 24.9% 372.5 286.5 30.0% Cost of Goods Sold 66.6 57.1 132.3 118.4 Gross Profit 125.8 96.9 29.8% 240.2 168.1 42.9% Gross Margin (%) 65.4% 62.9% 250 bps
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (₹ Crs) Sep-26 Mar-26 EQUITY AND LIABILITIES (₹ Crs) Sep-26 Mar-26 Non-Current Assets Equity Property, Plant and Equipment 336.2 331.4 Equity Share Capital 46.1 46.1 Capital Work-in-Progress 31.1 17.5 Other Equity 956.9 887.6 Right of Use Assets 23.7 13.9 Total Shar
Slide 11: Consolidated Abridged Cash Flow Statement
Consolidated Abridged Cash Flow Statement Cash Flow Statement (₹ crs) H1 FY27 H1 FY26 Profit/(Loss) Before Tax 87.0 67.1 Adjustments for Non-Cash and Non-Operational Expenses / (Incomes) 36.2 7.8 Operating Profit / (Loss) Before Working Capital Changes 123.2 74.9 Changes in Working Capital (84.7) (4
Slide 12: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed Amount utilized till Amount unutilized as No. Object as per Offer Document in Offer Document and 30th September 2026 on 30th September as Revised (₹ Crs) (₹ Crs) 2026 (₹ Crs) Investment in one of our Subsidiaries, Havix, to fund capital expe
Slide 13: Growth Strategies
Growth Strategies Private & Confidential
Slide 14: Growth Strategies
Growth Strategies Significantly enhance market Inorganic growth through synergistic acquisitions presence in North America & other Regulated Markets Integrated approach by Launch products with the potential enhancing capabilities for of NDA approval in the US backward integration Expanding into new
Slide 15: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 16: Introduction to Senores Pharmaceuticals
Introduction to Senores Pharmaceuticals Brief Overview Global Research driven Formulation Focused company engaged in developing & At a Glance manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada, UK and others across various therapeutic areas Niche Produ
Slide 17: Corporate Structure
Corporate Structure Senores Pharmaceuticals Inc. US based company holding ANDAs 100% Marketing cum ANDA and mutually exclusive marketing Subsidiary Holding Company relationships with customers Engaged in the Contract Aavis Pharmaceuticals Development & Manufacturing of 73.28% 1 Manufacturing arm of
Slide 18: Key Events & Milestones
Key Events & Milestones Acquired a 51% stake in Zoraya Incorporated a wholly owned Consolidated presence in emerging Pharmaceuticals, LLC (Nov 2025) Incorporated as “Senores subsidiary, Senores Pharmaceuticals markets by acquiring shares in Ratnatris Acquired 75% stake in Apnar Pharmaceuticals Pvt.
Slide 19: Key Strengths of the Company
Key Strengths of the Company Distinct Specialty and Complex Product Portfolio built in a short span for Regulated Markets Direct access to the US Government supplies through its subsidiary Enabling Forward Integration via our subsidiary, catering directly to B2C and Veterinary market Strong R&D capa
Slide 20: Four Business Segments
Four Business Segments 71% 20% 5% 4% FY26 Revenue Regulated Markets Emerging Markets Branded Generics Others ₹ 192 Crs Regulated Markets Business Emerging & Mid-Tier Markets Business Develop & manufacture pharmaceutical products for the Primarily serves the US, Canada and United Kingdom Emerging & M
Slide 21: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 22: Distinct Specialty & Complex Product Portfolio Built in a Short Span
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to Propel Products from Conception to Commercialization Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Partner Finalization Concurre
Slide 23: Amerisyn – Unlocking the US Government Pharmaceutical Market
1 Amerisyn – Unlocking the US Government Pharmaceutical Market The team comes with a experience of a The Joint Venture is with a team of decade in Government procurement Veterans of Army and Air Force. across Pharmaceuticals, Healthcare and Defence sectors. Direct supplies to the US Federal The Join
Slide 24: Zoraya – A step towards Forward Integration
1 Zoraya – A step towards Forward Integration Existing sales and distribution platform Partnered with a company with 15 years allows immediate access to buyers of of on-field experience in direct marketing. Generic and branded prescription drug in the US market Zoraya is Senores’ strategic U.S. anch
Slide 25: Presence in the Emerging & Mid-Tier Markets with Portfolio
3 Presence in the Emerging & Mid-Tier Markets with Portfolio including Specialty and Niche Products Special Focus Niche & Specialty patented products in the US with early launch 641 opportunity in Emerging Markets 40+ 123 South East Asia Countries Commonwealth of Sugammadex Ferric Marketed Independe
Slide 26: Branded Generics Business – Key Highlights
1 Branded Generics Business – Key Highlights Key Partners 60+ Products Launched 100+ Total Employees 200+ Hospitals Served 26
Slide 27: Professional and Experienced Management Team (1/2)
6 Professional and Experienced Management Team (1/2) Sanjay Shaileshbhai Majmudar Swapnil Jatinbhai Shah Deval Rajnikant Shah Chairman & Non-Executive, Promoter & Managing Director Whole-Time Director & CFO Non- Independent Director ▪ Nearly 2 decades of experience in the pharma sector ▪ 40+ years o
Slide 28: Professional and Experienced Management Team (2/2)
6 Professional and Experienced Management Team (2/2) Jignesh Desai Gautam Shah Jatin Gajjar President - Finance President - US Operations Chief Technology Officer ▪ 30+ years of experience in finance and accounting ▪ 30+ years of experience in pharmaceutical ▪ 30+ years of experience in pharmaceutic
Slide 29: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA Research Oral Oral Internal research ORS Injectables API In-House R&D in US for Solids Liquids Information available Controlled Substances on subscribed databases Team R&D Site 2 - India 107 people & 3 members Consolid
Slide 30: Accredited FDF Manufacturing Facilities (1/2)
5 Accredited FDF Manufacturing Facilities (1/2) Atlanta Facility Ahmedabad, Chhatral Facility 378,943 Sq. Ft. Total Area Facility 12 3 Manufacturing Lines Manufacturing Lines 185,300 Sq. Ft. 4 Total Area Dosage Forms General Oral Beta Lactum Strong Regulatory Track Record Dosage Injectables Orals US
Slide 31: Accredited FDF Manufacturing Facilities (2/2)
Accredited FDF Manufacturing Facilities (2/2) Apnar Pharma Plant ✓ Manufacturing facility commenced in 2021 & USFDA Approval received in September 2022 & in September 2026. ✓ 2 land parcel available of total land area of ~49,250 Sq. Mts. ✓ Facility constructed on 1 plot (~4,500 Sq. Mts) with constru
Slide 32: Accredited API Manufacturing Facilities
Accredited API Manufacturing Facilities Senores API Plant I & II ✓ GMP and WHO-GMP Approved sites ✓ Land parcel of 15,134 sq. ft. and 230,000 sq. ft. respectively. ✓ Employee Strength: 110+ Employees ✓ The facility integrates manufacturing with an advanced Quality Control Lab dedicated to testing an
Slide 33: Great Place to Work with Active Member of Globally recognized Pharma Associations
3 Great Place to Work with Active Member of Globally recognized Pharma Associations Active Member of Various Globally Recognized Great Place To Work Certified Pharmaceutical Associations & Working Bodies 33
Slide 34: Senores Pharmaceuticals Limited – Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98
Senores Pharmaceuticals — H1 FY27 Earnings Presentation on 6ix